Sugi Predict

Sugi Predict / Compounds / SCHEMBL27815331

SCHEMBL27815331

SCHEMBL27815331

CCCCCCCCCCCCCCCCOC(CC(N)=O)OCCCCCCCCCCCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.47
▸ DNM1 Q05193 1/20 0.46
▸ CA1 P00915 8/20 0.42
▸ CA2 P00918 8/20 0.42
▸ CA9 Q16790 7/20 0.42
▸ CA12 O43570 3/20 0.42
▸ CA7 P43166 3/20 0.42
▸ CA14 Q9ULX7 3/20 0.42
▸ CA3 P07451 2/20 0.42
▸ CA4 P22748 2/20 0.42
▸ CA6 P23280 2/20 0.42
▸ CA5A P35218 2/20 0.42
▸ CA5B Q9Y2D0 2/20 0.42
▸ NAAA Q02083 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ MMP8 P22894 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8692930 1.00 LMNA (0.47) LMNADNM1CA1CA2CA9
SCHEMBL16412341 1.00 LMNA (0.47) LMNADNM1CA1CA2CA9
SCHEMBL31252971 0.82 GPR84 (0.50) LMNAMAPT
Acetic Acid SCHEMBL10719151 0.79 GPR84 (0.47) LMNACES2MAPTMMP9MMP8
SCHEMBL10719159 0.77 NAAA (0.47) LMNADNM1NAAACES2
SCHEMBL4141679 0.76 DNM1 (0.53) LMNADNM1NAAACES2NPC1
SCHEMBL4137634 0.74 ALOX15 (0.40) LMNA
SCHEMBL17363975 0.74 LMNA (0.41) LMNADNM1CA1CA2NPC1
SCHEMBL8821928 0.74 LMNA (0.59) LMNAMAPT
SCHEMBL7780370 0.74 NAAA (0.48) LMNANAAANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4487869-A2 RNA ENCODING A TUMOR ANTIGEN CureVac SE (DE) 2025-01-08 — — EP claimed
US-20240091344-A1 MERS CORONAVIRUS VACCINE CureVac SE (DE) 2024-03-21 — — US claimed
EP-3595715-B1 RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY CureVac SE (DE) 2026-05-27 — — EP disclosed
US-20260137769-A1 NUCLEIC ACID MOLECULES AND USES THEREOF CureVac SE (DE) 2026-05-21 — — US disclosed
US-20260137768-A1 ZIKA VIRUS VACCINE CureVac SE (DE) 2026-05-21 — — US disclosed
EP-4735007-A2 IN VITRO TRANSCRIPTION METHOD Seqirus Inc. (US) 2026-05-06 — — EP disclosed
US-12618060-B2 Nucleic acid molecules CureVac SE (DE) 2026-05-05 — — US disclosed
US-20260091101-A1 BUNYAVIRALES VACCINE CureVac SE (DE) 2026-04-02 — — US disclosed
US-20260090989-A1 LIPID NANOPARTICLE mRNA VACCINES CureVac SE (DE) 2026-04-02 — — US disclosed
US-20260071224-A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION CureVac SE (DE) 2026-03-12 — — US disclosed
US-12569549-B2 Flavivirus vaccine CureVac SE (DE) 2026-03-10 — — US disclosed
EP-4023755-A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION CureVac AG (DE) 2022-07-06 — — EP disclosed
EP-3341482-B1 ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC AG (DE) 2022-07-06 — — EP disclosed
US-11345920-B2 Artificial nucleic acid molecules for improved protein expression CUREVAC AG (DE) 2022-05-31 — — US disclosed
US-20220144877-A1 RNA SEQUENCE ADAPTATION CUREVAC AG (DE) 2022-05-12 — — US disclosed
US-20220136001-A1 ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC AG (DE) 2022-05-05 — — US disclosed
US-20220096616-A1 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) CUREVAC AG (DE) 2022-03-31 — — US disclosed
US-11286492-B2 Artificial nucleic acid molecules for improved protein expression CUREVAC AG (DE) 2022-03-29 — — US disclosed
US-20220090092-A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION CUREVAC AG (DE) 2022-03-24 — — US disclosed
CN-101874112-A Nucleic acid of formula I): GlXmGn, or (II): ClXmCn, in particular as an immune-stimulating agent/adjuvant CUREVAC GMBH 2010-10-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345920-B2 Artificial nucleic acid molecules for improved protein expression NSUN3, CPSF6, CPSF1 LMNA 1661/4885DNM1 2945/4885CA1 3039/4885
US-12618060-B2 Nucleic acid molecules TP53, MICA, TAP1 LMNA 3545/4885DNM1 1667/4885CA1 164/4885
US-20220090092-A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION CPSF6, CPSF1, RNMT LMNA 1042/4885DNM1 3991/4885CA1 3058/4885
US-11286492-B2 Artificial nucleic acid molecules for improved protein expression CPSF6, CPSF1, RNMT LMNA 1042/4885DNM1 3991/4885CA1 3058/4885
US-20260071224-A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION RNGTT, RNMT, NSUN3 LMNA 1486/4885DNM1 3862/4885CA1 3815/4885
US-20240091344-A1 MERS CORONAVIRUS VACCINE SARS1, RNMT, ACE2 LMNA 1313/4885DNM1 1168/4885CA1 4486/4885
US-20260091101-A1 BUNYAVIRALES VACCINE RNGTT, RNMT, TIA1 LMNA 2478/4885DNM1 4612/4885CA1 3939/4885
US-12569549-B2 Flavivirus vaccine LNPK, PCTP, CETP LMNA 263/4885DNM1 4327/4885CA1 4698/4885
US-20260137768-A1 ZIKA VIRUS VACCINE ADAR, RNGTT, UPF1 LMNA 685/4885DNM1 4424/4885CA1 3887/4885
US-20260137769-A1 NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, RNGTT, NSUN3 LMNA 1098/4885DNM1 4082/4885CA1 2907/4885
US-20260090989-A1 LIPID NANOPARTICLE mRNA VACCINES RNMT, NSUN3, SARNP LMNA 359/4885DNM1 3277/4885CA1 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.